Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: In the control of pests in gas-tight spaces using gaseous phosphine, concentrated phosphine gas is passed through a phosphine-permeable dividing wall and then immediately combined with air to give phosphine-air mixtures with concentrations below self-ignition limits. Control of pests in gas-tight spaces comprises: (a) providing a source of phosphine (PH3) in concentrated form; (b) conducting the concentrated gaseous phosgene from the source into an air stream through a PH3-permeable dividing wall such that the introduced PH3 is immediately diluted at its point of introduction to below the concentration limits for self-ignition of PH3-air mixtures; and (c) introducing the resulting PH3-air mixture into the space to be fumigated.

Abstract: Process and generator for generating a pesticidal gas mixture of phosphine gas and air for fumigating an enclosed environment, e.g. a grain silo with phosphine. Air, moisture content adjusted by drying or humidifying, is passed through a porous bed of aluminum phosphide or magnesium phosphide, preferably in a throw-a-way cartridge. The resulting mixture of air and phosphine gas is passed into the space. Typical humidities (which determines the phosphine concentration) are 4 g/m.sup.3 for "flow through" conditions or 12 g/m.sup.3 for "one shot" conditions of fumigation. The cartridge is fitted directly in sealing relationship between inlet and outlet adaptors to serve as the gas generator vessel of the apparatus. The cartridge, completely filled with metal phosphide in powder or granulate form, has cylindrical gas-tight side walls, flexible and stretchable to allow for expansion of the metal phosphide during hydrolysis, and porous end walls.

Abstract: Process and generator for generating a pesticidal gas mixture of phosphine gas and air for fumigating an enclosed environment, e.g. a grain silo, with phosphine. Air, moisture content adjusted by drying or humidifying, is passed through a porous bed of aluminum phosphide or magnesium phosphide, preferably in a throw-a-way cartridge. The resulting mixture of air and phosphine gas is passed into the space. Typical humidities (which determines the phosphine concentration) are 4 g/m.sup.3 for "flow through" conditions or 12 g/m.sup.3 for "one shot" conditions of fumigation. The cartridge is fitted directly in sealing relationship between inlet and outlet adaptors to serve as the gas generator vessel of the apparatus. The cartridge, completely filled with metal phosphide in powder or granulate form, has cylindrical gas-tight side walls, flexible and stretchable to allow for expansion of the metal phosphide during hydrolysis, and porous end walls.

Abstract: Apparatus for generating a pesticidal gas mixture of phosphine gas and air for fumigating an enclosed environment, e.g. a grain silo, with phosphine. Air, moisture content adjusted by drying or humidifying, is passed through a porous bed of aluminium phosphide or magnesium phosphide, preferably in a throw-a-way cartridge. The resulting mixture of air and phosphine gas is passed into the space. Typical humidities (which determines the phosphine concentration) are 4 g/m.sup.3 for "flow through" conditions or 12 g/m.sup.3 for "one shot" conditions of fumigation. The cartridge is fitted directly in sealing relationship between inlet and outlet adaptors to serve as the gas generator vessel of the apparatus. The cartridge, completely filled with metal phosphide in powder or granulate form, has cylindrical gas-tight side walls, flexible and stretchable to allow for expansion of the metal phosphide during hydrolysis, and porous end walls.